NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

This is a research study for a new treatment for liver cancer. The trial is designed to compare the effectiveness of a three-drug combination with a placebo in patients with untreated liver cancer. The three drugs being studied are atezolizumab, bevacizumab, and tiragolumab. Atezolizumab is an immune checkpoint inhibitor, bevacizumab targets a protein that helps tumors grow new blood vessels, and tiragolumab is an investigational drug that is thought to work by stimulating the immune system to fight cancer.

Placebo: A placebo is a substance or treatment that has no active medical properties but is given to a patient as if it were a real medication or treatment. It is often used in medical research to compare the effects of a new drug or treatment with the effects of no treatment at all. The idea is to see if the new drug or treatment is genuinely effective by comparing how patients who receive the real treatment fare compared to those who receive the placebo

Immune checkpoint inhibitor: The immune system can help fight cancer. Drugs called “checkpoint inhibitors” work by releasing a natural brake on your immune system so that immune cells can recognize and attack tumors.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05904886

Clinical Trial Site: Einstein

To see all available clinical trials click here.